Search

Your search keyword '"Pol Stanislas"' showing total 348 results

Search Constraints

Start Over You searched for: Author "Pol Stanislas" Remove constraint Author: "Pol Stanislas" Journal journal of hepatology Remove constraint Journal: journal of hepatology
348 results on '"Pol Stanislas"'

Search Results

1. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis

2. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

3. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

4. Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

5. Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus

7. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death

8. Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status

9. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

10. WED-245 Should specific cutoffs be used for diagnosing fibrotic MASH in patients with type 2 diabetes using FAST, MAST, MEFIB and FNI?

11. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204

13. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy

14. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort

15. WED-391 Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)

16. OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis

18. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study

19. OS-060 Hepatocellular carcinoma development despite histological regression of liver fibrosis following HCV cure (ANRS CirVir, Hepather, LICAVIR)

21. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes

22. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis

23. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis

24. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

25. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients

26. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection

27. Prospective direct comparisons of four widespread non-invasive fibrosis tests (NITs) in outpatients with type-2 diabetes (T2D) using EPoS histological staging as reference

28. Platelet, elastography, age, sex and etiology for hepatocellular carcinoma surveillance in patients with advanced chronic liver disease: Please algorithm

29. HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort

30. Phenotypic characteristics of primary liver cancer in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study

31. Treatment with Bulevirtide, with or without PEG-interferon, in HIV-HBV/HDV co-infected patients in a real-life setting

35. Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)

36. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

37. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin

41. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection

44. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders

45. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

50. PAGE-B and FIB-4 predict the occurence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study

Catalog

Books, media, physical & digital resources